Table 1.
Characteristics of the aspirin‐compliant and non‐compliant ET subgroups and of the overall study population at randomization
|
ALL N = 243 |
Compliant N = 218 |
Non‐compliant N = 25 |
P value a | |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 112 (46.1) | 104 (47.7) | 8 (32.0) | 0.20 |
| Female | 131 (53.9) | 114 (52.3) | 17 (68.0) | |
| Age at enrollment | 60.0 [51.0; 67.0] | 60.0 [52.0; 67.0] | 54.0 [45.0; 66.0] | 0.07 |
| Time since ET diagnosis | 5.0 [2–10] | 5.0 [2–10] | 5.0 [3–12] | 0.60 |
| BMI, kg/m2 | 25.0 [22.9; 27.3] | 24.9 [22.8; 27.0] | 25.5 [23.4; 29.0] | 0.71 |
| Leukocytes, ×109/L | 7.00 [5.7; 8.5] | 7.00 [5.70; 8.4] | 7.67 [5.6; 9.7] | 0.39 |
| Hematocrit, % | 41.7 [39.2; 44.3] | 41.7 [39.0; 44.3] | 41.8 [39.9; 44.6] | 0.72 |
| Platelet count, ×109/L | 521 [422; 641] | 516 [422; 629] | 573 [434; 712] | 0.16 |
| TXB2 (ng/mL serum) | 19.0 [9.20; 42.6] | 18.6 [8.93; 42.9] | 23.3 [13.6; 38.8] | 0.54 |
| TXM (pg/mg creatinine) | 428 [318; 618] | 434 [319; 628] | 386 [310; 575] | 0.80 |
| JAK2‐V617F, n (%) b | ||||
| Wild type | 99 (40.9) | 88 (40.6) | 11 (44.0) | 0.91 |
| Mutated | 143 (59.1) | 129 (59.4) | 14 (56.0) | |
| CALR mutation, n (%) c | ||||
| Type 1 | 19 (14.8) | 19 (16.4) | 0 (0) | 0.34 |
| Type 2 | 16 (12.5) | 15 (12.9) | 1 (8.3) | |
| Other c | 93 (72.7) | 82 (70.7) | 11 (91.7) | |
| Cytoreductive therapy, n (%) d | ||||
| No | 98 (40.3) | 84 (38.5) | 14 (56.0) | 0.14 |
| Yes | 145 (59.7) | 134 (61.5) | 11 (44.0) | |
| Microvascular symptoms | ||||
| No | 218 (89.7) | 194 (89.0) | 24 (96.0) | 0.49 |
| Yes | 25 (10.3) | 24 (11.0) | 1 (4.00) | |
| Previous thrombosis, n (%) e | ||||
| No | 234 (96.3) | 209 (95.9) | 25 (100) | 0.60 |
| Yes | 9 (3.70) | 9 (4.13) | 0 (0.00) | |
Out of 218 fully compliant patients, 134 (61%) were on cytoreductive treatment (110 hydroxyurea (HU), 19 anagrelide, one interferon‐2alpha, 3 interferon‐2beta, and one a non‐specified agent) and they were analyzed together.
BMI, body mass index; ET, essential thrombocythemia; TX, thromboxane.
P value: Quantitative values are reported as median (interquartile range), unless otherwise specified. There were no significant differences between the different groups, based on the Kruskal‐Wallis test or chi‐square test for continuous or discrete variables.
One patient had no JAK2‐V617F genotype (in the compliant group).
Includes the following genotypes: CALR‐negative, CALR mutations other than type I or type II and MPL mutations. CALR was not genotyped in 115 patients (102 in the compliant group, 13 in the not compliant group).
In the 218 fully compliant patients, 110 were taking HU, 19 anagrelide, one interferon‐2alpha, three interferon‐2beta, and one a non‐specified agent.
Defined as any major thrombosis occurring within 2 years before diagnosis and at any time afterward.